Clinical study for neoadjuvant therapy of anti-PD-1 drug sintilimab combined with radical surgery in treating phase IB - IIIA non-small cell lung cancer patients
Latest Information Update: 27 Sep 2022
At a glance
- Drugs Sintilimab (Primary) ; Antineoplastics; Carboplatin; Gemcitabine; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Sep 2022 Results (n=50) assessing the safety and effectiveness of neoadjuvant PD-1 inhibitor sintilimab in addition to chemotherapy in the management of resectable stage IIIA non-small cell lung cancer, published in the Annals of Thoracic Surgery.
- 06 Jan 2020 Status changed from not yet recruiting to recruiting.
- 30 Sep 2019 New trial record